Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Michaelis

Showing results (191-200 of 214) with videos related to

Pageof 22
Sort By:
Journal of the National Cancer Institute|November 12, 2009
Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53Tom Van Maerken, Liesbeth Ferdinande, Jasmien Taildeman, et al.
Journal for Immunotherapy of Cancer|July 7, 2025
Precision targeting of rhabdomyosarcoma by combining primary CAR NK cells and radiotherapyLisa Marie Reindl, Lida Jalili, Tobias Bexte, et al.
Journal of Medical Virology|March 10, 2023
Repurposing of the antibiotic nitroxoline for the treatment of mpoxDenisa Bojkova, Nadja Zöller, Manuela Tietgen, et al.
Frontiers in Oncology|February 24, 2022
Artesunate Inhibits the Growth Behavior of Docetaxel-Resistant Prostate Cancer CellsOlesya Vakhrusheva, Holger H H Erb, Vitus Bräunig, et al.
The New England Journal of Medicine|December 28, 2022
Drug Sensitivity of Currently Circulating Mpox VirusesDenisa Bojkova, Marco Bechtel, Tamara Rothenburger, et al.
Cancers|June 2, 2021
Assessment of PI3K/mTOR/AKT Pathway Elements to Serve as Biomarkers and Therapeutic Targets in Penile CancerAnita Thomas, Sascha Reetz, Philipp Stenzel, et al.
Cancers|April 12, 2022
Value of c-MET and Associated Signaling Elements for Predicting Outcomes and Targeted Therapy in Penile CancerAnita Thomas, Kimberly Sue Slade, Roman A Blaheta, et al.
Genome Research|August 7, 2010
Susceptibility to chronic pain following nerve injury is genetically affected by CACNG2Jonathan Nissenbaum, Marshall Devor, Ze'ev Seltzer, et al.
Cancer Letters|April 29, 2025
Using a novel panel of drug-resistant triple-negative breast cancer cell lines to identify candidate therapeutic targets and biomarkersHelen E Grimsley, Magdalena Antczak, Ian G Reddin, et al.
Molecular Cancer|May 28, 2026
AcTor, a novel mTOR stimulator, potentiates ixazomib for the treatment of acute myeloid leukemiaShakti P Pattanayak, Odai Darawshi, Omid Hajihassani, et al.
Pageof 22

Showing results (191-200 of 214) with videos related to

Sort By:
Pageof 22
Journal of the National Cancer Institute|November 12, 2009
Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53Tom Van Maerken, Liesbeth Ferdinande, Jasmien Taildeman, et al.
Journal for Immunotherapy of Cancer|July 7, 2025
Precision targeting of rhabdomyosarcoma by combining primary CAR NK cells and radiotherapyLisa Marie Reindl, Lida Jalili, Tobias Bexte, et al.
Journal of Medical Virology|March 10, 2023
Repurposing of the antibiotic nitroxoline for the treatment of mpoxDenisa Bojkova, Nadja Zöller, Manuela Tietgen, et al.
Frontiers in Oncology|February 24, 2022
Artesunate Inhibits the Growth Behavior of Docetaxel-Resistant Prostate Cancer CellsOlesya Vakhrusheva, Holger H H Erb, Vitus Bräunig, et al.
The New England Journal of Medicine|December 28, 2022
Drug Sensitivity of Currently Circulating Mpox VirusesDenisa Bojkova, Marco Bechtel, Tamara Rothenburger, et al.
Cancers|June 2, 2021
Assessment of PI3K/mTOR/AKT Pathway Elements to Serve as Biomarkers and Therapeutic Targets in Penile CancerAnita Thomas, Sascha Reetz, Philipp Stenzel, et al.
Cancers|April 12, 2022
Value of c-MET and Associated Signaling Elements for Predicting Outcomes and Targeted Therapy in Penile CancerAnita Thomas, Kimberly Sue Slade, Roman A Blaheta, et al.
Genome Research|August 7, 2010
Susceptibility to chronic pain following nerve injury is genetically affected by CACNG2Jonathan Nissenbaum, Marshall Devor, Ze'ev Seltzer, et al.
Cancer Letters|April 29, 2025
Using a novel panel of drug-resistant triple-negative breast cancer cell lines to identify candidate therapeutic targets and biomarkersHelen E Grimsley, Magdalena Antczak, Ian G Reddin, et al.
Molecular Cancer|May 28, 2026
AcTor, a novel mTOR stimulator, potentiates ixazomib for the treatment of acute myeloid leukemiaShakti P Pattanayak, Odai Darawshi, Omid Hajihassani, et al.
Pageof 22